Citius Oncology (Nasdaq:CTOR) - Stock Price, News & Analysis

CTOR Stock Overview

Focuses on the development of novel targeted oncology therapies.

CTOR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months

Less than 3 years of financial data is available

Citius Oncology, Inc. Competitors

Kinnate Biopharma

NasdaqGS:KNTE

US$125.1m

Genetron Holdings

NasdaqGM:GTH

US$127.3m

Decibel Therapeutics

NasdaqGS:DBTX

US$124.3m

Adagene

NasdaqGM:ADAG

US$124.0m

Price History & Performance

Summary of all time highs, changes and price drops for Citius Oncology
Historical stock prices
Current Share Price	US$1.77
52 Week High	US$49.00
52 Week Low	US$1.53
Beta	0
11 Month Change	-85.62%
3 Month Change	-84.43%
1 Year Change	-83.47%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-82.46%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	CTOR	US Biotechs	US Market
7D	-13.2%	0.1%	0.5%
1Y	-83.5%	14.0%	22.7%

Return vs Industry: CTOR underperformed the US Biotechs industry which returned 14% over the past year.

Return vs Market: CTOR underperformed the US Market which returned 22.7% over the past year.

Price Volatility

Is CTOR's price volatile compared to industry and market?
CTOR volatility
CTOR Average Weekly Movement	73.1%
Biotechs Industry Average Movement	10.4%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Stable Share Price: CTOR's share price has been volatile over the past 3 months.

Volatility Over Time: CTOR's weekly volatility has increased from 40% to 73% over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	n/a	n/a

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.

Citius Oncology, Inc. Fundamentals Summary

How do Citius Oncology's earnings and revenue compare to its market cap?
CTOR fundamental statistics
Market cap	US$126.21m
Earnings (TTM)	-US$19.52m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-6.5x

P/E Ratio

Is CTOR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CTOR income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$19.52m
Earnings	-US$19.52m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.27
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did CTOR perform over the long term?

See historical performance and comparison